NCT00240045View on ClinicalTrials.gov

The Use of Drugs to Improve Kidney Function in Patients With Liver and Kidney Dysfunction

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

October 31, 2005

Study Completion Date

July 31, 2007

Conditions
Type 2 Hepatorenal SyndromeRefractory Ascites
Interventions
DRUG

Midodrine, albumin, octreotide LAR

DRUG

midodrine, octreotide, albumin

midodrine up to 12.5 mg tid, octreotide LAR 20 mg im once, albumin 150 mg q weekly

Trial Locations (1)

T6G 2E1

University of Alberta, Edmonton

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

University of Alberta

OTHER